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Abstract  
Introduction: in this study, it is aimed to emphasize the causes and importance of macrocytosis in paediatric practice. Methods: in the paediatric 
hematology and oncology clinic, 1752 patients evaluated in 2017, patients with macrocytosis were examined retrospectively with clinical and 
laboratory findings. Patients with macrocytosis were compared with the frequency of severe hematologic diseases such as acute leukemia and bone 
marrow failure in patients with normocytic and microcytic mean corpusculer volume. Results: macrocytosis was detected in 72 out of 1752 patients 
(4.1%) in the study. Acute lymphoblastic leukemia in 11(15.2%), acute myeloid leukemia in 3(4.1%), Fanconi aplastic anemia in 7(9.7%), Diamond-
Blackfan anemia in 2(2.7%), aplastic anemia in 1(1.3%), congenital diseritropoetic anemia in 1(1.3%), deficiency of vitamin B12 in 14(19.4%) were 
diagnosed. Down syndrome was presented in 33 cases (45.8%). The number of patients with acute leukemia diagnosis was 14(0.8%) in the group 
in which the mean corpusculer volume was either microcytic or normocytic. The incidence of acute leukemia and bone marrow failure was significantly 
higher in the group with macrocytosis compared between the two groups. Conclusion: although vitamin B12 deficiency is considered firstly in 
patients who have undergone cytopenia and macrocytosis in our country, haematological malignancies, bone marrow failures, myelodysplasia and 
myeloproliferative diseases should be remembered especially in the individuals with Down syndrome at the same time. 
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Introduction 
 
Erythrocytes are classified into three morphological groups by their 
mean cell volume (MCV): microcytic, normocytic, and macrocytic. 
Macrocytosis is the enlargement of erythrocytes more than 2 standard 
deviations than the normal value of the age group. The classification 
by MCV also constitutes the foundation of anemia classification used 
mostly in clinical practice. Although MCV values vary by age and sex, 
reticulocyte count and other series are considered important for the 
examination of patients [1]. Macrocytic anemias are classified into 
two groups: one is associated with the megaloblastic changes in bone 
marrow and the other is non-megaloblastic anemia characterized by 
macrocytosis. Ninety five percent of megaloblastic anemias are 
caused by deficiency of vitamin B12 and/or folate. Whereas the most 
frequent causes of non-megaloblastic macrocytosis are neonatal 
period, reticulocytosis, liver dysfunction, aplastic anemias, and 
myelodysplastic syndromes [2, 3]. The aim of the present study is to 
underline the causes and significance of macrocytosis in clinical 
paediatric practice in Pamukkale University Faculty of Medicine and 
Diyarbakir Children Hospital Paediatric Hematology-Oncology clinics. 
 
 
Methods 
 
Retrospective analysis of the clinical and laboratory findings of 1752 
patients, who were examined in the paediatric hematology and 
oncology outpatient clinics in a one year period during January-
December 2017 were included. To identify the etiology, blood count, 
peripheral smear, bone-marrow aspiration and biopsies, erythrocyte 
sedimentation rate, kidney-liver-thyroid function tests, a-fetoprotein 
(AFP), hemoglobin F (HbF), vitamin B12 and folate levels were 
evaluated. Patients whose MCV values were more than 2 standard 
deviations than the normal value of the age group were grouped in 
macrocytosis. Etiology was investigated in these patients. There was 
any exclusion criteria in the study and variable datas are collected 
from our clinic archive. Prevalence rates of any severe hematological 
diseases such as acute leukemia and bone marrow deficiency were 
compared between macrocytic and normocytic or microcytic groups. 
Ethics committee approval was obtained for the study (30.01.18/03). 
Statistical analyses: all the descriptive analyses were performed by 
Statistical Package for the Social Sciences 22.0 (SPSS Inc.; Chicago, 
IL, USA). For the comparison of the categorical variables, Fisher Chi-
Square test was used. 
Results 
 
Macrocytosis was detected in 72 of 1752 patients. The mean age of 
patients with macrocytosis were 5.7 (3 months to 17 years) years and 
44(61.2%) were male and 28(38.2%) were female. Eleven patients 
(15.2%) were diagnosed with acute lymphoblastic leukemia (ALL), 
3(4.1%) with acute myeloid leukemia (AML), 7(9.7%) with Fanconi 
aplastic anemia (FAA), 2(2.7%) with Diamond-Black fan anemia 
(DBA), one (1.3%) with aplastic anemia, one (1.3%) with congenital 
dysery thropoietic anemia (CDA), and 14(19.4%) with vitamin B12 
deficiency. In 33(45.8%) of the cases, the diagnosis of Down 
syndrome (DS) was present. Patients with ALL consisted of 3 T-cell 
ALL and 8 pre-B cell ALL. Types of patients with AML were M0, M6 
and M7. The most frequent cause for presentation and referral is the 
suspected cytopenia and malignancy. No history of a chronic disease 
except DS and no established drug use in the etiology of macrocytosis 
were present. Vitamin B12 and folate deficiency diagnosis was based 
on serum levels of vitamin B12 (normal value >200 pg/ml), folate 
(normal value>4.1 ng/ml), hemogram, and the findings of peripheral 
smear (hypersegmented neutrophils-the presence of neutrophils with 
six or more lobes or the presence of more than 3% of neutrophils 
with at least five lobes) and clinical evaluation. When 10 patients with 
bone marrow deficiency were evaluated, the high levels of HbF were 
detected in all, only mild high levels of AFP was found in only 2 
patients with FAA. 
In the clinical and laboratory investigations of three (4.1) cases, no 
underlying cause that may lead to macrocytosis and no associated 
cytopenia were established. In 28 (84.8%) of 33 patients with DS and 
two (14.2%) of 14 patients with vitamin B12 deficiency no signs for 
cytopenia were observed. Of 25 patients with acute leukemia and 
bone marrow deficiency one had isolated mild thrombocytopenia, 
three had anemia, one neutropenia-leukopenia, and the remaining 
20(80%) had either bicytopenia or pancytopenia. While one patient 
with acute leukemia had a moderate increase in liver function tests, 
one patient with DS was having treatment for hypothyroidism (Table 
1). The number of patients diagnosed with acute leukemia was 
14(0.8%) in microcytic or normocytic group (n=1680) by MCV values. 
Although patients with pancytopenia or bicytopenia caused by 
infections were included, they were not given the diagnosis of bone 
marrow deficiency. In the comparison of the macrocytic group to 
microcytic or normocytic group by MCV values, the prevalence of 
acute leukemia and bone marrow deficiency was found significantly 
higher in macrocytosis group (p< 0.001) (Table 2). In the evaluation 
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of the patients with Down syndrome within itself, of 106 patients with 
DS, 33(33.1%) had macrocytosis. Two patients with macrocytosis 
were diagnosed with AML-M6 and ALL at the time of the first 
admission. One patient was diagnosed with myelofibrosis based on 
bone marrow biopsy examined upon cytopenia and hypocellularity of 
bone marrow aspiration confirmed at outpatient follow up visit. This 
patient developed AML-M7, identified at follow up after 7 months. The 
comparison between the groups with and without macrocytosis 
showed that the prevalence of acute leukemia was significantly higher 
in patients with DS (Table 3). 
 
 
Discussion 
 
Macrocytosis is caused by four main mechanisms. These include 
nutritional deficiencies, bone marrow disorders, medication, and 
chronic diseases [4]. Macrocytosis is rarely observed in children 
compared to normocytic or microcytic conditions, based on MCV [5]. 
In our study, the prevalence of macrocytosis was 4.1% in 1752 
patients. Although there are no studies on frequency in children in 
the literature, macrocytosis prevalence estimates ranging from 1.7% 
to 3.6% in adults [5, 6]. Our study had almost similar results when 
compared to the literature. Macrocytic anemias are classified as 
megaloblastic and non-megaloblastic. Non-megaloblastic anemia is 
associated with liver disease, hypothyroidism, bone marrow 
deficiencies, and MDS. The most common cause of megaloblastic 
anemia in children is vitamin B12 deficiency [5]. In our study, patients 
diagnosed with vitamin B12 deficiency were either suffering from 
accompanying iron deficiency or carriers of thalassemia, macrocytosis 
could only be identified in 14 patients. Failing to assess the utilization 
tests for vitamin B12 such as the measurements of serum 
concentrations of homocysteine and methylmalonic acid is considered 
as a limitation in diagnosing vitamin B12 deficiency. Pappo et al. [7] 
in their study in 146 children identified the causes of macrocytosis as 
medication (51 patients), congenital heart disease (20), Down 
syndrome (12), bone marrow deficiency or MDS (6), and various 
chronic diseases (21). However, in 24 of them the cause of anemia 
could not be determined. In our study, acute leukemia, bone marrow 
deficiency, Down syndrome, and vitamin B12 deficiency were the 
leading causes. No history of medication was present. The reason the 
distribution of diagnoses differed in our study than that of Pappo et al. 
study has been considered as the result of overlooking of MCV values 
in patients without cytopenia and failing to refer them to paediatric 
hematology outpatient clinics. Erythrocytes in neonatal period tend to 
be physiologically macrocytic. In post neonatal period the upper limit 
of MCV decreases to 85 fL; over 6 months of age, the upper limit is 
calculated with MCV=84+0.6xAGE formula [8]. Patients in neonatal 
period were not included in our study. Individuals with Down 
syndrome also constitute a patient group with high prevalence for 
macrocytosis. In evaluation studies, macrocytosis was the most 
frequently obtained hematological finding in DS [9]. In a study by 
Prasher et al., macrocytosis was identified as the most frequent 
symptom in 147 adult patients [10]. In our cases, 33 of 106 patients 
with DS were determined to have macrocytosis. Two patients with 
macrocytosis had lower levels of vitamin B12. Since the levels of 
vitamin B12 and folic acid measurements were not performed in all 
DS cases with macrocytosis, no correlation between vitamin B12 and 
folic acid in this group of patients could be established. However, in 
previous studies, vitamin B12, and folic acid deficiency, and increased 
levels of hemoglobin F have not been determined as the underlying 
cause of macrocytosis in individuals with DS [11]. 
Macrocytosis may be encountered as the earliest symptom in bone 
marrow deficiencies, and in MDS. Macrocytosis may be detected even 
in cases with normal blood count, and responsive to treatment [12]. 
Macrocytosis and thrombocytopenia FAA are the most frequently 
obtained laboratory findings. Cytopenias usually occur at around the 
age of 5-10 years with a mean age of 7. In patients presenting with 
a congenital anomaly, and growth and developmental delay, if 
macrocytosis is present in blood count, then FAA should be suspected 
[13]. DBA and CDA are bone marrow deficiency syndromes, of which 
the former is associated with erythroid cell aplasia, and the latter is 
characterized by morphological abnormalities in erythrocytes and by 
ineffective erythropoiesis that affects isolated erythroid series. 
Majority of the patients have macrocytic anemia [14]. In our study, 
seven FAA, two DBA, one aplastic anemia, and one CDA patient had 
cytopenia and macrocytosis in their blood counts performed for 
diagnostic assessment (Table 1). Acute leukemia is the most common 
malignity of childhood accounts for 1/3 of all childhood malignancies. 
Although the etiology of acute leukemia has not been understood 
clearly, genetical abnormalities mainly include aberrations in 
karyotypes, chromosomal translocations, and deletions. Typical 
examples are Down syndrome and FAA. Laboratory findings may 
include leukocytosis, leukopenia, thrombocytopenia, and anemia. 
Anemia usually takes the form of normochromic normocytic anemia 
accompanied with reticulocytopenia [14]. In our study, of 28 patients 
diagnosed with acute leukemia, 14 (50%) had macrocytosis, and 14 
(50%) had microcytic or normocytic MCV values. The prevalence for 
acute leukemia was higher in patients with macrocytosis (Table 2). 
Compared to normal population, children with DS have an increased 
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risk of developing acute leukemia and MDS [15]. Majority of the 
patients with lymphoid leukemia show immuno-phenotypic features 
of precursor B cell ALL. In patients with DS, unlike the myeloid 
leukemia, lymphoid leukemias are not observed during the period of 
infancy. Due to intrinsic drug resistance and treatment related 
mortalities, prognosis was worse than that of lymphoid leukemia, 
which occurs sporadically [16, 17]. The incidence of AML was found 
to be 150 times more in children with DS. The most common form of 
AML in children with DS is the AML-M7 acute mega karyoblastic 
leukemia [18]. AML-M6 and AML-M1/M2 are less frequent than AML-
M7 in patients with DS [19, 20]. In our 106 cases with DS, three of 
them developed acute leukemia. They were diagnosed with AML-M6, 
AML-M7 and ALL. Within the patients with DS, comparison between 
the groups with and without macrocytosis showed a significantly 
higher incidence of acute leukemia (Table 3). 
 
 
Conclusion 
 
Macrocytosis is a significant symptom in the diagnosis of bone marrow 
diseases and acute leukemia in childhood. Although, given the 
present conditions of our country, vitamin B12 deficiency is the first 
suspect in patients with cytopenia and macrocytosis, yet 
haematological malignancies, bone marrow deficiencies (congenital 
or acquired), myelodysplasia, and myeloproliferative diseases should 
be borne in mind especially in the individuals with Down syndrome, 
as well. 
What is known about this topic 
 Macrocytosis is rarely observed in children compared to 
normocytic or microcytic conditions, based on MCV; 
 The most common causes in the literature are drugs and 
chronic diseases; 
 The number of studies done on children about macrocytosis 
and etiology is not enough. 
What this study adds 
 Macrocytosis can be an alarm finding for suspicion of bone 
marrow pathologies; 
 In individuals with Down syndrome, patients with 
macrocytosis should be more closely monitored for 
myelodysplastic syndrome and acute leukemia. 
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Table 1:  characteristics of patients with macrocytosis, acute leukemia and bone marrow failure 
Patient 
  
Diagnosis Age Gender Wbc 
/mm3 
Neut 
/mm3 
Hgb 
gr/dl 
MCV Plt 
/mm3 
Physical examination LFT TFT B12-folat 
1 AML M0 8 Male 41.990 8100 7,1 99 24.000 HSM N - N 
2 AML M6-DS 2 Female 12.980 1200 5,6 93 50.000 HSM N N N 
3 ALL 11 Female 44.780 440 5,4 94 14.000 HSM-LAP N - N 
4 ALL 4 Male 8270 180 7,5 89 24.000 HSM-LAP N N N 
5 ALL 15 Male 12.290 290 3,7 94 6000 HSM-LAP N N N 
6 ALL 8 Female 7670 1160 7,3 93 263.000 HSM-LAP N N N 
7 ALL 4 Male 7470 210 7,2 101 171.000 HSM-LAP N - - 
8 ALL 6 Female 12.690 260 7,3 90 26.000 HSM-LAP N - - 
9 ALL 10 Male 3920 270 6,6 94 67.000 HSM N N - 
10 ALL 3 Female 3320 600 11,4 89 193.000 HSM 2 fold increase N N 
11 ALL 7 Male 39.630 540 6,6 94 34.000 HSM-LAP N - N 
12 ALL 12 Female 57.980 1370 3,4 107 67.000 HSM-LAP N N N 
13 ALL-DS 6 Female 26.850 880 5,5 102 25.000 HSM-LAP N N N 
14 FAA 11 Female 1860 220 8,5 98 38.000 GR, Cafe-au-lait spots N N N 
15 FAA 5 Male 3810 330 8,2 94 26.000 GR, Cafe-au-lait spots N N N 
16 FAA 4 Male 5710 1180 12 96 144.000 GR N N N 
17 FAA 5 Male 4020 2030 12,2 93 74.000 GR, Cafe-au-lait spots N N N 
18 FAA 5 Month Male 9820 3560 5,4 101 323.000 microcephaly N N N 
19 FAA 6 Female 4320 1840 11,7 96 26.000 GR, Cafe-au-lait spots N N N 
20 FAA 2 Female 3330 1340 10,2 90 65.000 GR, Cafe-au-lait spots N N N 
21 AA 14 Female 2190 470 8,2 100 32.000 - N N N 
22 DBA 2 Male 5260 1520 7,5 103 462.000 GR N N N 
23 DBA 1,5 Female 9920 2820 6 89 446.000 - N N N 
24 CDA 13 Female 4740 3470 2,5 104 240.000 - N N B12: 146 
25 MFS-AML 
M7-DS 
11 Month Male 3170 890 5 94 17.000 HSM N N 
Treated for 
hypothyroidism 
N 
Wbc: White blood cell count, neut: neutrophil count, hgb: hemoglobin, plt: thrombocyte count, MCV: Mean corpusculer volume, LFT: liver function tests, TFT:Thyroid function tests, AML: 
acute myeloid leukemia, ALL: acute lymphoid leukemia, FAA: Fanconi aplastic anemia, AA: aplastic anemia, DBA: Diamond–Blackfan anemia, CDA: congenital dysery thropoetic anemia, 
MFS: myelofibrozis, DS: Down syndrome, HSM: hepatosplenomegaly, LAP: lymphadenopathy, GR: Growth retardation 
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Table 2: comparison of the incidence of acute leukemia and bone marrow failure 
  Patients diagnosed with acute leukemia 
and bone marrow failure 
Patients without acute leukemia and 
bone marrow failure 
Total 
case 
pvalue 
Macrocytosis 25 47 72 p<0,001 
Microcytic, 
normocytic 
14 1666 1680 
Chi-square test 
 
 
 
Table 3: comparison of the incidence of acute leukemia and myelodysplastic syndrome between patients with macrocytosis and 
without macrocytosis in Down syndrome 
  Patients diagnosed with acute 
leukemia and MDS 
Patients without acute leukemia and 
MDS 
Total case pvalue 
Macrocytosis 3 30 33 0,028 
Microcytic, 
normocytic 
0 73 73 
Fisher Ex: test 
 
